Bio-Techne (TECH) return on equity (ROE)

Return on equity · fiscal 2026
8.6%

Bio-Techne (TECH) earned a return on equity of 8.6% in fiscal 2026 (the year ended June 30, 2026). That is 4.8 percentage points higher than the 3.8% of fiscal 2025. Figures as of 17 Nov 2026, 20:27 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2026
8.6%
Change on fiscal 2025
+4.8 pts
Highest on record
23.1%fiscal 2009
Lowest on record
3.8%fiscal 2025
Fiscal years on record
182009–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Bio-Techne return on equity (ROE), in more detail

Across the 18 fiscal years on record (2009–2026), the highest was 23.1% in fiscal 2009 and the lowest 3.8% in fiscal 2025. The fiscal 2026 figure is higher than in 24% of the 17 earlier fiscal years on record, whose median is 14.0%.

History · 18 fiscal years

Return on equity by fiscal year

Bio-Techne return on equity (ROE), year by year

Bio-Techne (TECH) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
20268.6% 4.8 pts up
20253.8% 4.3 pts down
20248.1% 6.4 pts down
202314.5% 1.5 pts down
202216.0% 7.0 pts up
20219.0% 7.6 pts down
202016.6% 8.4 pts up
20198.2% 3.4 pts down
201811.7% 3.7 pts up
20178.0% 3.9 pts down
201611.9% 0.8 pts down
201512.7% 1.2 pts down
201414.0% 1.3 pts down
201315.3% 1.4 pts down
201216.7% 2.5 pts down
201119.2% 2.7 pts down
201021.9% 1.2 pts down
200923.1%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Bio-Techne and comparable companies
CompanyReturn on equityFiscal year
DaVita DVA773.1%2024
Halozyme Therapeutics HALO649.2%2025
Universal Health Services UHS20.5%2025
Repligen RGEN2.3%2025
Bio-Techne TECH8.6%2026
BioMarin Pharmaceutical BMRN5.7%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on TECH

Bio-Techne, figure by figure

Bio-Techne (TECH) overview: price, valuation and scorecardAll health care companies by market value

Bio-Techne return on equity (ROE): questions and answers

What is Bio-Techne's return on equity?

Bio-Techne (TECH) earned a return on equity of 8.6% in fiscal 2026 (the year ended June 30, 2026). That is 4.8 percentage points higher than the 3.8% of fiscal 2025.

Is Bio-Techne's return on equity high or low compared with its own history?

The fiscal 2026 figure is higher than in 24% of the 17 earlier fiscal years on record, whose median is 14.0%.

What are the highest and lowest return on equity figures on record for Bio-Techne?

Across the 18 fiscal years on record (2009–2026), the highest was 23.1% in fiscal 2009 and the lowest 3.8% in fiscal 2025.

How is Bio-Techne's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Bio-Techne (TECH) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/TECH/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.